US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

463.06

+9.342.06%

Number of Gainers:5

Number of Losers:- -

Number of Flat:- -

PE:- -

High:465.70

Open:452.82

Low:443.80

Close:453.72

Volume:9.43M

Turnover:130.15M

Market Cap:9.91B

Float Cap:9.09B

Loading ...

Beam Therapeutics Inc. published an update to their financial calendar

Editas Medicine to Participate in Upcoming Investor Conferences

Beam Therapeutics Initiated at Buy by Canaccord Genuity

Beam Therapeutics initiated with a Buy at Canaccord

Intellia Therapeutics Inc. to Host Conference Call on Q4 and Full-Year 2025 Financial Results and Business Updates

Press Release: ONE Gas Announces Fourth Quarter and Full Year 2025 Financial Results; Releases Non-GAAP Adjusted Financial Guidance

Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors

Simply Wall St.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)

Assessing Beam Therapeutics (BEAM) Valuation After New Patent Agreement Secures Base Editing IP Access

Simply Wall St.

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital

CRISPR Therapeutics Ag : TD Cowen Raises Target Price to $45 From $40

THOMSON REUTERS

Switzerland's CRISPR Therapeutics misses Q4 revenue expectations

Wedbush Remains a Buy on Beam Therapeutics (BEAM)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":463.06064,"timestamp":1771880399999,"preClose":453.72366,"halted":0,"volume":9434991,"delay":0,"changeRate":0.020579,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":9.336975,"latestTime":"02-23 16:00:00 EST","open":452.82303,"high":465.6976,"low":443.80396,"amount":130154731.690282,"amplitude":0.048253,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771923600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.68728,"peRate":-5.611469,"turnoverRate":0.012818,"increases":5,"decrements":0,"flats":0,"marketCap":9912922320,"floatMarketCap":9091302880},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":465.6976,"amplitude":0.048253,"preClose":453.72366,"low":443.80396,"pbRate":"2.68728","latestPrice":463.06064,"volume":9434991,"delay":0,"open":452.82303,"prevYearClose":431.70972,"prevWeekClose":453.7237,"prevMonthClose":444.3123,"prevQuarterClose":431.7097,"fiveDayClose":449.2727,"twentyDayClose":494.3327,"sixtyDayClose":405.3747,"secType":"PLATE","market":"US","turnoverRate":0.012818,"peRate":-5.611469,"marketCap":9912922320,"floatMarketCap":9091302880,"timestamp":1771880399999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2613382737","title":"Beam Therapeutics Inc. published an update to their financial calendar","url":"https://stock-news.laohu8.com/highlight/detail?id=2613382737","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613382737?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:00","pubTimestamp":1771880411,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc. will announce its fourth quarter and full year 2025 financial results and a new liver-targeted genetic disease program on an investor webcast on Tuesday, February 24, 2026, at 8:00 a.m. ET. The live webcast will be available in the investor section of www.beamtx.com and will be archived for 60 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDLbWPf2X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","SG9999014021.USD","LU1861558580.USD","BEAM","BK4556","LU1861559042.SGD","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","LU0314104364.USD","LU2210150020.SGD","BK4611","IE00B64PRP62.GBP","LU2210149790.SGD","BK4505","SG9999014039.USD","BK4588","IE00BKPKM429.USD","BK4139","SG9999014013.SGD","LU2095319765.USD","NDAQ","SG9999014005.SGD","BK4585","BK4112"],"gpt_icon":0},{"id":"2613787035","title":"Editas Medicine to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613787035","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613787035?lang=en_us&edition=fundamental","pubTime":"2026-02-23 22:00","pubTimestamp":1771855200,"startTime":"0","endTime":"0","summary":"ir@editasmed.com. media@editasmed.com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242678/0/en/Editas-Medicine-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","BK4556","BK4139"],"gpt_icon":0},{"id":"2613129204","title":"Beam Therapeutics Initiated at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2613129204","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613129204?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BEAM/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 20, 2026 16:01 ET (21:01 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","LENZ","BK4505","BK4539","BK4535","BK4611","BK4588","LU1861558580.USD","BK4007","BK4585","BK4139","LU1861559042.SGD","BEAM"],"gpt_icon":0},{"id":"2612261526","title":"Beam Therapeutics initiated with a Buy at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2612261526","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612261526?lang=en_us&edition=fundamental","pubTime":"2026-02-20 19:56","pubTimestamp":1771588595,"startTime":"0","endTime":"0","summary":"Canaccord analyst Whitney Ijem initiated coverage of Beam Therapeutics (BEAM) with a Buy rating and $74 price target The company’s last 12-18 month...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beam-therapeutics-initiated-with-a-buy-at-canaccord-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","LU1861559042.SGD","BK4535","BK4585","BK4007","BK4588","BK4539","LU1861558580.USD","BEAM","BK4139","BK4556","BK4505","BK4611"],"gpt_icon":0},{"id":"2612402078","title":"Intellia Therapeutics Inc. to Host Conference Call on Q4 and Full-Year 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2612402078","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612402078?lang=en_us&edition=fundamental","pubTime":"2026-02-19 20:31","pubTimestamp":1771504271,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics said it will host a conference call on February 26, 2026 at 8 a.m. ET to discuss its fourth-quarter and full-year 2025 financial results and business updates. The call will be accessible via webcast at link.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260219:nNDL2NmWh8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SG9999014013.SGD","BK4112","LU1861558580.USD","LU1861559042.SGD","LU0314104364.USD","SG9999014005.SGD","SG9999014039.USD","NTLA","NDAQ","BK4556","IE00BKPKM429.USD","BK4535","IE00B64PRP62.GBP","LU2095319765.USD","LU2210149790.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","BK4585","IE00BGHQF748.EUR","SG9999014021.USD","BK4588"],"gpt_icon":0},{"id":"2612429049","title":"Press Release: ONE Gas Announces Fourth Quarter and Full Year 2025 Financial Results; Releases Non-GAAP Adjusted Financial Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2612429049","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612429049?lang=en_us&edition=fundamental","pubTime":"2026-02-19 05:20","pubTimestamp":1771449600,"startTime":"0","endTime":"0","summary":"Analyst call and webcast scheduled tomorrow, Feb. 19 at 11 a.m. EST. TULSA, Okla., Feb. 18, 2026 /PRNewswire/ -- ONE Gas, Inc.  today announced its fourth quarter and full year 2025 financial results, which include diluted earnings per share of $1.42 and $4.37, respectively. The Company also provided non--GAAP adjustments to both earnings and its 2026 financial guidance to capture the full impact of a regulatory mechanism intended to mitigate regulatory lag. Adjusted net income was $1.48 per diluted share for the fourth quarter, and $4.48 per diluted share for the full year 2025. For 2026, non--GAAP earnings are expected to range from $306 million to $314 million, or $4.83 to $4.95 per diluted share.\"Our team delivered strong operational and financial results in 2025, reflecting disciplined execution and a commitment to safely serving our communities,\" said Robert S. McAnnally, president and chief executive officer. \"Looking ahead, we see meaningful opportunity in both residential and ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EDIT","LU0566484027.USD","LU1559883803.SGD","BK4556","BK4197","OGS","BK4139"],"gpt_icon":0},{"id":"2612413479","title":"Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2612413479","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612413479?lang=en_us&edition=fundamental","pubTime":"2026-02-18 13:25","pubTimestamp":1771392322,"startTime":"0","endTime":"0","summary":"Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing the gene editing trial to resume.\nThe decision follows updates to safety protocols after rare adverse events were evaluated.\nThe cleared pathway enables expanded enrollment for MAGNITUDE-2 and continued work on Intellia's in vivo gene editing program.\n\nFor you as an investor looking at Intellia Therapeutics (NasdaqGM:NTLA), this regulatory step comes as the stock trades at $12.22. The share price...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/clinical-hold-lift-on-magnitude-2-resets-risk-reward-for-int","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/clinical-hold-lift-on-magnitude-2-resets-risk-reward-for-int","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4535","LU1861558580.USD","LU1861559042.SGD","BK4211","BK4588","BK4556","NTLA","ISBC","BK4585"],"gpt_icon":0},{"id":"2611485675","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)","url":"https://stock-news.laohu8.com/highlight/detail?id=2611485675","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611485675?lang=en_us&edition=fundamental","pubTime":"2026-02-16 21:10","pubTimestamp":1771247427,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report), M...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-crispr-therapeutics-ag-crsp-moderna-mrna-and-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-crispr-therapeutics-ag-crsp-moderna-mrna-and-disc-medicine-iron-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","XBI","AG","BK4611","BK4210","HCSG","BK4581","BK4588","LU0128526141.USD","LU1861558580.USD","BK4551","BK4139","XLV","BK4548","LU0053671581.USD","CRSP","BK4533","BK4501","BK4568","LU0029874061.USD","BK4534","LU1861559042.SGD","MRNA","BK4585","BK4556","BK4137","BK4532","IRON"],"gpt_icon":0},{"id":"2611120088","title":"Assessing Beam Therapeutics (BEAM) Valuation After New Patent Agreement Secures Base Editing IP Access","url":"https://stock-news.laohu8.com/highlight/detail?id=2611120088","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611120088?lang=en_us&edition=fundamental","pubTime":"2026-02-16 00:27","pubTimestamp":1771172864,"startTime":"0","endTime":"0","summary":"Patent agreement puts Beam Therapeutics (BEAM) intellectual property in focus\nBeam Therapeutics (BEAM) has moved to secure its gene editing toolkit, signing a standby license agreement with Kobe University and Bio Palette that aims to protect access to key base editing patents.\nSee our latest analysis for Beam Therapeutics.\nThe standby license news lands after a choppy year, with a 26.79% 90 day share price return but a 1 year total shareholder return of 13.83% decline, signaling near term...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/assessing-beam-therapeutics-beam-valuation-after-new-patent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-beam/beam-therapeutics/news/assessing-beam-therapeutics-beam-valuation-after-new-patent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4136","BK4556","LU1861558580.USD","BEAM","LU1481599808.USD","BK4585","BK4611","LU1487256676.USD","IP","LU1861559042.SGD","LU1169590202.USD","IE00B3T34201.USD","BK4588","BK4535","LU1481600234.SGD","BK4505","BK4139","LU1169589451.USD","LU2463526074.USD"],"gpt_icon":0},{"id":"2611167307","title":"CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2611167307","media":"Benzinga","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611167307?lang=en_us&edition=fundamental","pubTime":"2026-02-14 02:45","pubTimestamp":1771008349,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics highlights progress in clinical trials &amp; uptake of Casgevy gene therapy. Pipeline also advancing with promising data.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/02/50621927/crispr-therapeutics-spotlights-momentum-for-lead-gene-therapy-as-adoption-widens","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014914.USD","LU2089283258.USD","LU2471134796.USD","LU1551013342.USD","BK4585","LU2168563687.JPY","LU1868836757.USD","SG9999001176.USD","LU2211815571.USD","BK4007","LU1712237335.SGD","LU2462157665.USD","LU1057294990.SGD","CRSP","LU2168564065.EUR","SG9999018865.SGD","LU0820561909.HKD","LU1988902786.USD","LU1720051017.SGD","SG9999014898.SGD","IE00B19Z3581.USD","LU0943347566.SGD","LU1629891620.HKD","LU2491050071.SGD","SG9999001176.SGD","IE00B19Z9Z06.USD","IE0005OL40V9.USD","LU0683600562.USD","LU2237443465.HKD","LU2756315318.SGD","LU0823434740.USD","BK4567","GB00BDT5M118.USD","SGXZ57979304.SGD","LU0823434583.USD","SGXZ51526630.SGD","BK4581","LU0889565916.HKD","LU2237443895.HKD","LU1674673428.USD","IE00BKPKM429.USD","LU0882574139.USD","IE00BZ9MQY76.HKD","LU0786609619.USD","SG9999014906.USD","IE00BKDWB100.SGD","LU0106261372.USD","LU0323591593.USD","LU0820561818.USD","LU0058720904.USD","BK4588","LU0353189763.USD","LU1430594728.SGD","LU0787776722.HKD","LU1868837300.USD","LU1093756168.USD","LU0672654240.SGD","LU2237438978.USD","LU2360106947.USD","LU0823416689.USD","LU2237443978.SGD","LU2362541273.HKD","LU1868836591.USD","LU2087625088.SGD","LU2471134523.USD","IE00BJJMRY28.SGD","LU2361044949.HKD","BK4534","LU0225283273.USD","LU0320765059.SGD","LU2168564495.EUR","LU0471298777.SGD","BK4139","LU0354030511.USD","LU0096364046.USD","IE00BJJMRX11.SGD","LU0640476718.USD","IE00BN29S564.USD","LU2168564222.USD","LU0094547139.USD","LU2552382132.HKD","LU0109391861.USD","LU0114720955.EUR","LU1145028129.USD","LU2237443622.USD","IE00BFTCPJ56.SGD","LU2023250504.SGD","SG9999015986.USD","LU0353189680.USD","SGXZ99366536.SGD","LU0158827781.USD","LU2106854487.HKD","LU2471134952.CNY","LU1868836914.USD","LU0158827948.USD","LU0234570918.USD","LU0471298694.HKD","LU0708995401.HKD","LU1548497426.USD","LU0097036916.USD","LU2271345857.HKD","LU1804176565.USD","BK4611","LU0203202063.USD","LU2417539215.USD","LU2357305700.SGD","LU0316494557.USD","IE0002141913.USD","IE00B4JS1V06.HKD","IE00BFSS7M15.SGD","SG9999013999.USD","LU1267930730.SGD","ELIS","LLYZ","LU0689472784.USD","LU1814569148.SGD","LU1023059063.AUD","LU2362541513.USD","IE00B1XK9C88.USD","IE00BK4W5M84.HKD","LU2756315664.SGD","BK4516","IE00BWXC8680.SGD","LU1974910355.USD","LU2361044865.SGD","LU2111349929.HKD","LU0053666078.USD","SG9999014880.SGD","LU0432979614.USD","LU2471134879.HKD","IE00BJT1NW94.SGD","LU2552382058.USD","LU0266013472.USD","LU1861558580.USD","LU2750360641.GBP","LU1989771016.USD","LU1064131342.USD","SG9999017495.SGD","LU2236285917.USD","LU1861559042.SGD","LU2491049909.HKD","LU0198837287.USD","LU2362540622.SGD","LU2456880835.USD","LU0210536198.USD","ELIL","LU2023251221.USD","LU2089984988.USD","IE00B4R5TH58.HKD","LU1623119135.USD","LU2112291526.USD","SGXZ31699556.SGD","LU0234572021.USD","IE00B775H168.HKD","LU0079474960.USD","LU0256863902.USD","LU1551013425.SGD","LU1280957306.USD","LU2361045086.USD","LU0061475181.USD","LU2028103732.USD","LU1917777945.USD","BK4556","BK4532","LU2491050154.USD","LU1983299246.USD","IE00BK4W5L77.USD","LU2746668974.SGD","LU2265009873.SGD","LU0882574055.USD","LU1323610961.USD","LU0456855351.SGD","LU0109394709.USD","LU2264538146.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","BK4533","LU0964807845.USD","LU2896262040.SGD","IE00B19Z9P08.USD","IE0009355771.USD","IE00B7KXQ091.USD","IE00B894F039.SGD","LU1868837136.USD","LU2213496289.HKD","LLYX","LU0256863811.USD","LU0354030438.USD","LU0385154629.USD","LU0203201768.USD","LU1069344957.HKD","LU2468319806.SGD","LU2746668461.USD","IE0004445015.USD","LU1291159041.SGD","LU2552382215.SGD","IE00B2B36J28.USD","LU1585245621.USD","LU1720051108.HKD","LU1127390331.HKD","LU1366192091.USD","LU0122379950.USD","LU2168564149.EUR","IE00B1BXHZ80.USD","LU1674673691.USD","IE00B19Z3B42.SGD","IE0004445239.USD","IE00BFSS8Q28.SGD","LU1232071149.USD","LU0289739699.SGD","LU1061106388.HKD","LU2750360997.AUD","IE00BJLML261.HKD","LU0320765992.SGD","SGXZ81514606.USD","SG9999015952.SGD","LU2023250330.USD","LU2089284900.SGD","LU2237443382.USD","LU2602419157.SGD","LU0466842654.USD","LU1035775433.USD","LU0820562030.AUD","LU2063271972.USD","LU1093756325.SGD","LU2108987350.USD","SG9999015978.USD","LU1778281490.HKD","SG9999015945.SGD","IE0002270589.USD","LU2461242641.AUD","SG9999018857.SGD","LU2237443549.SGD","LU0238689110.USD","BK4599","LU0417517546.SGD","LU0006306889.USD"],"gpt_icon":0},{"id":"2611154220","title":"Crispr Therapeutics AG (CRSP) Receives a Hold from RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2611154220","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611154220?lang=en_us&edition=fundamental","pubTime":"2026-02-13 20:37","pubTimestamp":1770986239,"startTime":"0","endTime":"0","summary":"In a report released today, Luca Issi from RBC Capital maintained a Hold rating on Crispr Therapeutics AG, with a price target of $50.00. Issi cove...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-hold-from-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crispr-therapeutics-ag-crsp-receives-a-hold-from-rbc-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4611","LU0310800379.SGD","LU0708994859.HKD","BK4207","BK4210","BK4585","BK4556","BK4588","CRSP","LU0128525929.USD","LU1861559042.SGD","LU1267930573.SGD","AG","LU1861558580.USD","LU0029864427.USD"],"gpt_icon":0},{"id":"2611827731","title":"CRISPR Therapeutics Ag : TD Cowen Raises Target Price to $45 From $40","url":"https://stock-news.laohu8.com/highlight/detail?id=2611827731","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611827731?lang=en_us&edition=fundamental","pubTime":"2026-02-13 14:05","pubTimestamp":1770962719,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260213:nFWN3Z9088:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRSP","LU1861559042.SGD","BK4588","BK4556","LU1861558580.USD","BK4611","BK4139","BK4585"],"gpt_icon":0},{"id":"2611080909","title":"Switzerland's CRISPR Therapeutics misses Q4 revenue expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2611080909","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611080909?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:41","pubTimestamp":1770932496,"startTime":"0","endTime":"0","summary":"Switzerland's CRISPR Therapeutics missesQ4 revenue expectationsOverviewSwitzerland-based gene editing firm's Q4 revenue missed analyst expectationsNet loss for Q4 widened significantly compared to the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nL1N3Z81IV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4556","BK4588","CRSP","BK4139","LU1861559042.SGD","LU1861558580.USD","BK4611"],"gpt_icon":0},{"id":"2610978542","title":"Wedbush Remains a Buy on Beam Therapeutics (BEAM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2610978542","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610978542?lang=en_us&edition=fundamental","pubTime":"2026-02-12 23:26","pubTimestamp":1770909984,"startTime":"0","endTime":"0","summary":"Wedbush analyst maintained a Buy rating on Beam Therapeutics today and set a price target of $57.00. In addition to Wedbush, Beam Therapeutics also...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-beam-therapeutics-beam-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-remains-a-buy-on-beam-therapeutics-beam-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4505","BK4535","LU1861559042.SGD","BEAM","BK4556","LU1861558580.USD","BK4588","BK4139","BK4611"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}